Last $241.28 USD
Change Today -3.11 / -1.27%
Volume 1.7M
ACT On Other Exchanges
Symbol
Exchange
Berlin
New York
Mexico
As of 8:04 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Morris Corporate Center III

400 Interpace Parkway

Parsippany, NJ 07054

United States

Phone: 862-261-7000

Fax:

Inc. (Itero), a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero’s recombinant follicle stimulating hormone (rFSH) product. In 2011, the company entered into the Amgen Inc. (Amgen) collaboration agreement. The collaboration products would be sold under a joint Amgen/Actavis label. Research and Development: Actavis Specialty Brands segment research and development expenses included $191.8 million, as of December 31, 2013. ANDA DISTRIBUTION This segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and OTC medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians’ offices. Additionally, the company sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. The company also distributes its own products and its collaborative partners’ products. The company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi. Business Strategy The company applies three strategies to achieve growth for its Actavis Pharma and Actavis Specialty Brands pharmaceutical businesses: internal development of differentiated and high-demand products, including, in certain circumstances, challenging patents associated with these products; establishment of strategic alliances and collaborations; and acquisition of products and companies that complement its business. Customers The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. The company distributes generic and brand pharmaceutical products to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains, physicians’ offices and buying groups. The company’s major customers include McKesson Corporation and Walgreens. Regulations The United States: All pharmaceutical manufacturers, including the company, are subject to extensive, complex and evolving regulation by the federal government, principally the U.S. Food and Drug Administration, and to a lesser extent, by the U.S. Drug Enforcement Administration (DEA), Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. Significant Events In February 2014, the company entered into a merger agreement with Forest Laboratories, Inc. In 2013, the company acquired Warner Chilcott plc, a specialty pharmaceutical company focused on women’s healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, primarily in North America. In 2013, the company entered into a license agreement with Medicines360 to market, sell and distribute Medicines360 LNG20 intrauterine device (LNG20) in the U.S. and Canada. In 2013, the company entered into an agreement to acquire the worldwide rights to Valeant Pharmaceuticals International, Inc.’s metronidazole 1.3% vaginal gel antibiotic development product, a topical antibiotic for the treatment of bacterial vaginosis. In 2013, the company acquired Belgium-based Uteron Pharma SA. In 2013, the company sold its Changzhou Watson Pharmaceuticals Co., Ltd business to Great Harmony Enterprises Limited. In April 2014, Particle Sciences announced that they have entered into an exclusive agreement with Actavis plc to develop an unnamed complex generic product. Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing. In July 2014, Hanmi Pharm. Co. Ltd. and Actavis plc have entered into 12 years collaboration for Hyalrheuma, hyaluronic acid injection for arth

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $241.28 USD -3.11

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.59 USD -0.31
Allergan Inc/United States $178.19 USD -1.51
Covidien PLC $86.51 USD -1.30
Shire PLC 5,300 GBp -40.00
Valeant Pharmaceuticals International Inc C$146.75 CAD +2.08
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings 100.0x
Price/Sales 4.2x
Price/Book 4.4x
Price/Cash Flow 44.7x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.